Figure 1. Immunoreactive GHR/GHBP in canine mammary tissue
and mammary tumors. The bar represents 50 µm. A,
High-power magnification of a duct in atrophic mammary tissue.
Immunoreactivity is located in both the epithelial and the
myoepithelial layers of the duct (x415). B, Mammary tissue in the
proliferation phase, characterized by ductal budding structures. Cells
in these buds are homogenously immunoreactive (x200). C, Mammary
tissue in the differentiation phase. Note that, in terminally
differentiated alveoli at the left-hand side of the
picture, the immunoreactivity is strongly diminished or absent
(x200). D, Canine complex adenoma. GHR/GHBP immunoreactivity is
present in both the spindle cell (*) and the epithelial component
(arrow) of the tumor (x200). E, Canine complex adenoma.
Negative control. Mab 263 is replaced by the unrelated HMB45 monoclonal antibody of the same
isotype (IgG1k) (x200). F, Canine solid mammary carcinoma.
Immunoreactivity is clearly heterogenous: immunopositive and
immunonegative areas are present in the tumor (x200). G, High-power
magnification of a canine solid mammary carcinoma. Several carcinoma
cells demonstrate nuclear immunoreactivity (arrow)
(x400).
